Risperidone-induced photosensitivity

Almond, Deborah; Rhodes, Lesley E.; Pirmohamed, Munir

doi:10.1136/pgmj.74.870.252

Cited by 10 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, antipsychotic and antidepressant treatment itself has been shown to cause cutaneous photosensitivity. The reactions may present with a wide morphological spectrum, ranging from sunburn-like responses to eczematous, lichenoid and even bullous lesions, resembling porphyria cutanea tarda (27)(28)(29)(30)(31).…”

Section: Discussionmentioning

confidence: 99%

Cutaneous photodamage in schizophrenia patients

Wohl

Aviv

Friedman

et al. 2008

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous photodamage in schizophrenia patients

Wohl

Aviv

Friedman

et al. 2008

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

show abstract

“…Furthermore, chlorpromazine can function as an activator of tyrosinase, an enzyme used to produce melanin. Also, risperidone cutaneous reactions are thought to be mediated by a similar mechanism [ 54 ].…”

Section: Antipsychotics As Potential Inducers Of Bpmentioning

confidence: 99%

Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature

et al. 2021

View full text Add to dashboard Cite

Neuropsychiatric disorders are found to be associated with bullous pemphigoid (BP), an autoimmune subepidermal blistering disease. Antipsychotics have emerged as possible inducing factors of BP. However, large sample studies concerning BP associated with antipsychotics, as well as with specific mental disorders, are still lacking. Our review retrieved a few clinical studies and case reports on the topic, producing controversial results. We report for the first time a bipolar patient case presenting BP following five-month therapy with risperidone long-acting injectable (LAI). We hypothesize that the dermatological event is associated with the medication administered. The issue emerged during psychiatric consultation and was confirmed by histological examination, direct and indirect immunofluorescence studies, plus positive plasma and cutaneous BP180 and BP230 IgG. Neurodegeneration or neuroinflammation might represent a primary process leading to a cross-reactive immune response between neural and cutaneous antigens and contributing to self-tolerance failure. Furthermore, the time sequence of the shared biological mechanisms leading to clinical manifestations of the neuropsychiatric disorder and BP remains undefined. BP comorbid with bipolar disorder might occasionally represent a serious health risk and affect patients’ physical and psychosocial quality of life. Thus, clinicians treating psychiatric patients should consider BP as a possible adverse effect of psychotropic medications.

show abstract